3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Prostatic Neoplasms
3
Lung Neoplasms
2
Disease
2
Colorectal Neoplasms
2
Acute Kidney Injury
2
Urinary Bladder Neoplasms
1
Tuberous Sclerosis
1
Smoldering Multiple Myeloma
1
Salivary Gland Adenoma, Pleomorphic
1
Renal Insufficiency
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Monoclonal Gammopathy of Undetermined Significance
1
Lymphangioleiomyomatosis
1
Kidney Neoplasms
1
Hemangiosarcoma
1
Glioma
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Dexamethasone
14
Lenalidomide
13
Calcium Dobesilate
7
carfilzomib
4
dexamethasone acetate
3
dexamethasone 21-phosphate
3
auricularum
3
Melphalan
3
Leflunomide
3
Curcumin
3
isatuximab
2
iberdomide
2
daratumumab
2
Denosumab
2
Cyclophosphamide
2
Bortezomib
2
selinexor
1
pomalidomide
1
poly ICLC
1
piperine
1
pembrolizumab
1
ixazomib
1
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
elotuzumab
1
citarinostat
1
atezolizumab
1
Urination
1
Transplantation, Autologous
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Smoldering Multiple Myeloma
×
Urination
×
Clear all
NCT03951220
2025-08-19
LOOMIS
Oxford University Hospitals NHS Trust
Completed
67 enrolled
24 charts